Gilead Sciences, Inc. GILD
166.53 USD -2.45 (-1.45%)
Regular-session close
166.66 +0.13 +0.08%
After hours · Nov 19, 7:08 PM ET
164.80 Day range 169.16
116.88 52-week range 176.58
- YTD
- +35.68%
- 1 year
- +30.03%
News
marketwatch.com Worried investors are paying up for these stocks — some with up to 49% upside, analysts say Defensive sectors have beaten the S&P 500 by a wide margin in recent months, even though they are priced much higher relative to earnings estimates than the index.
zacks.com Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
seekingalpha.com Gilead Sciences, Inc. (GILD) Presents at Jefferies Global Healthcare Conference 2026 Transcript Gilead Sciences, Inc. (GILD) Presents at Jefferies Global Healthcare Conference 2026 Transcript
benzinga.com Natera Short Interest Rises As Bets Remain Near September Peak Natera Inc. (NASDAQ:NTRA) short sellers added to their positions as of the latest settlement date.Short interest rose 3.77% to 6.07 million shares as of the Oct. 30 settlement date, from 5.85 million…
seekingalpha.com Gilead Sciences, Inc. (GILD) Presents at UBS Global Biopharma Conference 2026 Transcript Gilead Sciences, Inc. (GILD) Presents at UBS Global Biopharma Conference 2026 Transcript
marketbeat.com Gilead Sciences Maps Growth Beyond BIKTARVY With HIV, Cancer and Inflammation Drugs Gilead Sciences NASDAQ: GILD expects HIV and oncology to drive growth through the rest of the decade while it builds an inflammation business for the 2030s, executives said at a London healthcare…
businesswire.com Suffolk Celebrates Completion of Gilead Sciences Research Center With Ribbon Cutting FOSTER CITY, Calif.--(BUSINESS WIRE)--Suffolk, one of the most innovative and successful builders in the country, recently joined Gilead Sciences to celebrate the completion of its new Research…
benzinga.com Gilead Partners With Generic Manufacturers to Boost Future Access to Experimental Ebola Prevention Drug Gilead Sciences signs royalty-free licensing deals with three generic makers to support future Ebola antiviral access across 127 nations.
marketbeat.com Gilead Sciences Bets on HIV Prevention Growth Despite $1.5 Billion Biktarvy Headwind Gilead Sciences NASDAQ: GILD expects its expanding HIV prevention portfolio and a potential new cell therapy for multiple myeloma to support growth, even as a negotiated price change for its HIV…
fool.com These 3 Dividend Stocks Have Crushed the Market This Year. Here’s Why They Are Still Buys They have excellent long-term prospects.
businesswire.com Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has signed royalty-free voluntary licensing agreements with three generic manufacturers to support…benzinga.com Barclays Maintains Equal-Weight on Gilead Sciences, Raises Price Target to $160 Barclays analyst Emily Field maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and raises the price target from $145 to $160.
247wallst.com How Retirees Can Turn $50,000 Into Passive Income With These 4 Dividend Stocks Selling shares in a down market can lock in losses just when retirees need cash most. Four dividend payers from telecom, asset management, biopharma and pizza offer another route, though one of them…
defenseworld.net Gilead Sciences, Inc. $GILD Shares Acquired by Bessemer Group Inc. Bessemer Group Inc. increased its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 17.7% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange…
defenseworld.net Gilead Sciences, Inc. $GILD Stock: Fisher Asset Management LLC Raises Stake Fisher Asset Management LLC raised its position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 1,516.0% during the third quarter, according to its most recent Form 13F filing with the…
fool.com Which Healthcare ETF Is Best for the Long Term: State Street’s XPH or Invesco’s PBE? Lower fees and a steadier beta set one healthcare ETF apart, while the rival fund's richer dividend could sway income-focused investors.
247wallst.com Gilead Beat the S&P 500 by More Than 25 Points in the Past Year, but $1,000 From a Decade Ago Is Still Worth Less Than $3,500 Gilead has crushed the market over the past year, yet a longer view tells a very different story. A new HIV shot, a looming Medicare price cut, and a December FDA decision will shape which version of…
defenseworld.net 31,340 Gilead Sciences, Inc. $GILD Shares Bought by Aberdeen Group plc Aberdeen Group plc raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 3.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities…
zacks.com Can Gilead Sciences' HIV Business Fuel Sustainable Long-Term Growth? GILD's HIV franchise gains momentum as Yeztugo sales surge, Biktarvy maintains market leadership and an expanding pipeline strengthens long-term growth prospects.
marketbeat.com 3 Pharmaceutical Stocks That Offer Safety and Growth Market volatility is unpleasant, but it's important that investors don't force themselves into a false choice between safety and growth. Over the last two years, technology stocks, particularly AI…
defenseworld.net Gilead Sciences, Inc. $GILD Stock Sold by Allspring Global Investments Holdings LLC Allspring Global Investments Holdings LLC reduced its position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 33.6% in the third quarter, according to its most recent filing with the SEC. The…
benzinga.com EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat The next wave of U.S. drug-price negotiations could put billions of dollars in pharmaceutical revenue under pressure, with Eli Lilly and Co (NYSE:LLY), Gilead Sciences, Inc. (NASDAQ:GILD) facing more…
benzinga.com EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat Democrats have two ways to pressure drugmakers. Eli Lilly, Gilead, Merck, Bristol Myers face different levels of Medicare pricing exposure.
seekingalpha.com Gilead Sciences, Inc. (GILD) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript Gilead Sciences, Inc. (GILD) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript
benzinga.com Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.
benzinga.com Gilead Highlights Strong Trial Results in HIV Prevention and Liver Disease Gilead reports high persistence for twice-yearly HIV shot lenacapavir and strong Phase 3 Livdelzi response in primary biliary cholangitis.
benzinga.com Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 3.47% on an annualized basis producing an average annual return of 12.13%. Currently, Gilead Sciences has a market…benzinga.com Gilead’s Twice-Yearly HIV Prevention Injection Shows 85.6% Persistence And Zero HIV Acquisitions in 52-Week Trial Gilead Sciences, Inc. (NASDAQ:GILD) today announced results from the PURPOSE 5 trial showing significantly higher persistence—defined as consistent and continuous on-time use—among people starting…
benzinga.com Gilead Sciences Reports Phase 3 IDEAL Success For Livdelzi In PBC, With 75.4% Achieving ALP Normalization At Week 52 Vs 16.1% Placebo; Serious Adverse Events 3.1% Livdelzi Vs 12.9% Placebo; None Related To Drug - Data to be Presented at The Liver Meeting® Demonstrate Rapid and Sustained Improvements in ALP Levels with Livdelzi in Adults with PBC and ALP Levels Between 1-1.67× ULN, Despite Receiving UDCA or…
benzinga.com Gilead Sciences To Present 23 Presentations At 68th American Society of Hematology Annual Meeting Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced 23 presentations, including 7 oral presentations, will be presented at the 68th American Society of Hematology (ASH)…
benzinga.com Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 3.29% on an annualized basis producing an average annual return of 12.2%. Currently, Gilead Sciences has a market…benzinga.com JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $190 JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $170 to $190.
benzinga.com TD Cowen Maintains Buy on Gilead Sciences, Raises Price Target to $175 TD Cowen analyst Tyler Van Buren maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $160 to $175.
benzinga.com Morgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $183 Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $163 to $183.
benzinga.com Wells Fargo Maintains Overweight on Gilead Sciences, Raises Price Target to $190 Wells Fargo analyst Mohit Bansal maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $165 to $190.
benzinga.com Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $181 Truist Securities analyst Gregory Renza maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $158 to $181.
benzinga.com RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $131 RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target from $126 to $131.
benzinga.com Gilead CEO Takes Aim at Medicare Pricing: 'Pill Penalty' Threatens Drug Innovation Gilead stock rose after Q3 earnings beat Wall Street estimates and strong HIV drug demand prompted an increased 2026 sales forecast.
benzinga.com Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday Analysts raised targets for Cheniere and Incyte, while cutting Stryker, Roblox, Intel and Honeywell; Bright Horizons was downgraded.
benzinga.com These Analysts Increase Their Forecasts On Gilead Sciences After Upbeat Q3 Results Gilead beats Q3 estimates, raises 2026 sales guidance but cuts EPS outlook; shares rise 4.1% as analysts lift price targets.benzinga.com Cantor Fitzgerald Maintains Overweight on Gilead Sciences, Raises Price Target to $175 Cantor Fitzgerald analyst Carter Gould maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $155 to $175.
benzinga.com Needham Maintains Buy on Gilead Sciences, Raises Price Target to $200 Needham analyst Joseph Stringer maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $170 to $200.
benzinga.com Gilead Sciences Q3 2026 Earnings Call Transcript Gilead Sciences (NASDAQ:GILD) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…benzinga.com Gilead Sciences Lowers FY2026 GAAP EPS Guidance from $(3.75)-$(3.40) to $(4.40)-$(4.05) vs $(3.44) Est Gilead Sciences (NASDAQ:GILD) lowers FY2026 GAAP EPS guidance from $(3.75)-$(3.40) to $(4.40)-$(4.05) vs $(3.44) analyst estimate..
benzinga.com Gilead Sciences Lowers FY2026 Adj EPS Guidance from $(0.65)-$(0.30) to $(1.20)-$(0.85) vs $(0.47) Est; Raises FY2026 Sales Guidance from $30.100B-$30.400B to $31.000B-$31.300B vs $30.767B Est Gilead Sciences (NASDAQ:GILD) lowers FY2026 Adj EPS guidance from $(0.65)-$(0.30) to $(1.20)-$(0.85) vs $(0.47) analyst estimate. Raises FY2026 sales outlook from $30.100 billion-$30.400 billion to…
benzinga.com Gilead Sciences Q3 Adj. EPS $2.55 Beats $2.19 Estimate, Sales $8.300B Beat $7.809B Estimate Gilead Sciences (NASDAQ:GILD) reported quarterly earnings of $2.55 per share which beat the analyst consensus estimate of $2.19 by 16.44 percent. This is a 3.24 percent increase over earnings of…
benzinga.com Alphabet Sinks 11.8%, Small Caps Rally on Strong GDP Growth: Stock Market Today Alphabet's capex-heavy quarter drags the Nasdaq 100 lower while GDP beats and the Russell 2000 rallies, with three of four large caps rising.
benzinga.com Amazon, Eli Lilly On Deck Thursday As AWS Growth, Drug Demand Face Test Amazon headlines Thursday’s reports, with investors focused on whether accelerating AWS growth and heavy AI spending can support the next leg of its expansion. Eli Lilly, Mastercard, Merck,…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…benzinga.com Gilead Sciences Agrees To Acquire Oral IL-23R Inhibitor Program From PepStar Therapeutics Under $1.275B Deal Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar…
